Therefore, the well-established Eμ-Myc mouse model of B-cell lymphoma [39] is an ideal system to explore how different NF-κB subunits might regulate these processes and potentially affect treatment with CHK1 inhibitors. Here, NFKB1 is linked to B-cell non-Hodgkin lymphoma.